Trial Profile
Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Dalteparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Thrombosis; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms CASTA-DIVA
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Oct 2021 Results assessing the rivaroxaban is non-inferior to dalteparin for the treatment of VTE in patients with active cancer and a high risk of recurrent VTE, published in the Chest.
- 10 Aug 2018 Status changed from active, no longer recruiting to completed.